Mumbai 12th September : A study study that was conducted by the Tata Memorial Centre (TMC) has shown that a simple low-cost treatment can dramatically improve the rate of cure and survival for breast cancer patients top officials told here on Monday.The major multi-centre clinical trials conducted in women who had breast cancer surgery.
It was discovered that an injection of the drug commonly used around the tumor – right before surgery on the operating table – can dramatically increase the rate of cure and survival of the patients over the long term.
Director of TMC, Rajendra Badwe who was the one who conducted the research presented results at the ongoing European Society of Medical Oncology Congress in Paris on Monday.
the TMC’s Professor Sudeep Gupta spoke to the media about the results in Mumbai.
The results of the trial prove that the injection does not require additional expertise and is affordable just 100 rupees per person but could lead in saving at minimum 100,000 lives of breast cancer patients every year around the world, according to Badwe.
In contrast, expensive targeted drugs that cost more than 10 lakh for each patient have shown much less benefit in the early stages of breast cancer, according to the study entitled “Effect of Peri-Tumoral Infiltration of Local Anaesthetic Prior To Surgery on the Survival in Early Breast Cancer’.
The study was initiated by Badwe The study was carried out on 1600 women who were planning to undergo early breast cancer treatment at 11 cancer centers in India including TMC for 11 years from 2011 to 2022 According to Gupta.
“This is the first research of its kind to demonstrate significant benefits from a single treatment prior to surgery.For researchers this opens up a possibility of pre-operative interventions that can alter the condition of cancer in such a way to avoid its harmful reaction to surgery.” Badwe told the Paris conference.
Gupta stated in Mumbai that the cost-effective and quick-to-implement treatment in breast cancer is performed by any surgeon who is able to treat cancer, as demonstrated by a large, randomised trial that is considered to be the “gold gold standard’ of evaluating the worth of new treatments.
In the report the duo stated that half of the participants (out of the 1,600) were part of the “control group,” which were treated with standard surgery and the standard post-operative treatment that includes radiotherapy, chemotherapy and hormone therapy in accordance with guidelines.
Another half comprised the intervention group that received an injection of an ordinary local anaesthesia drug, 0.5 percent lidocaine all over the tumor just prior to the surgery and then underwent the same post-operative care similar to that of the control group.
After treatment, patients were monitored regularly for a number of years until the date of cut-off of September 2021, to compare the rates of cure and survival between the group of control as well as the group with local anaesthesia.
“As expected there was no toxic effect of the lignocaine in those who had the treatment (the injection).The six-year duration of disease-free survival was 81.7 percent in the group with no control, and 86.1 percent in the anaesthesia local group, for 26 per cent reduction in the chance of the occurrence of a fatal relapse or death, which is to be significant in the context of statistics.
The six-year over survival rate was 86.2 percent and 89.9 percent in both groups for a reduction of 29 per cent in mortality risk with the injection of local anaesthetic vitally important according to Badwe.
His previous research indicated the possibility of a window of possibility just before, during and shortly after the surgery removal of the primary tumor.
This is when anti-cancer treatments could decrease the chance of developing of spread-seminated metastatic cancer.Stage 4 metastatic cancer throughout the course of the patient’s life.
The hospitals where clinical trials were carried out were: TMC Mumbai, Kolhapur Cancer Centre, Sterling Multi-speciality Hospital, Pune, and Siddhivinayak Ganapati Cancer Hospital, Sangli (all Maharashtra); All India Institute of Medical Sciences and Max Superspeciality Hospital (both Delhi); B.Borooah Cancer Centre, Guwahati; Basavatarakam Indo-American Cancer Hospital and Research Centre Hyderabad; Gujarat Cancer & Research Institute, Ahmedabad; Malabar Cancer Centre, Thalassery (Kerala) and North-Eastern Indira Gandhi Regional Institute of Health & Medical Sciences, Shillong.
qn/arm
